Janux Therapeutics, Inc. (NASDAQ:JANX) CEO Sells $1,290,000.00 in Stock

Janux Therapeutics, Inc. (NASDAQ:JANX) CEO David Alan Campbell sold 25,000 shares of Janux Therapeutics stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $51.60, for a total transaction of $1,290,000.00. Following the completion of the sale, the chief executive officer now directly owns 257,054 shares in the company, valued at approximately $13,263,986.40. This represents a 8.86 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

David Alan Campbell also recently made the following trade(s):

• On Monday, October 28th, David Alan Campbell sold 25,000 shares of Janux Therapeutics stock. The stock was sold at an average price of $53.54, for a total transaction of $1,338,500.00.
• On Friday, September 27th, David Alan Campbell sold 25,000 shares of Janux Therapeutics stock. The shares were sold at an average price of $46.31, for a total value of $1,157,750.00.

Janux Therapeutics Stock Performance

Janux Therapeutics stock opened at $45.21 on Friday. The stock has a market cap of $2.37 billion, a P/E ratio of -38.64 and a beta of 3.52. Janux Therapeutics, Inc. has a fifty-two week low of $7.79 and a fifty-two week high of $65.60. The firm’s fifty day moving average price is $49.81 and its 200-day moving average price is $45.80.

Janux Therapeutics (NASDAQ:JANX) last announced its earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18). The business had revenue of $0.44 million during the quarter, compared to the consensus estimate of $1.50 million. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The business’s quarterly revenue was down 82.6% on a year-over-year basis. Sell-side analysts predict that Janux Therapeutics, Inc. will post -1.35 earnings per share for the current year.

Institutional Investors Weigh In On Janux Therapeutics

Several hedge funds have recently bought and sold shares of JANX. Franklin Resources Inc. increased its holdings in shares of Janux Therapeutics by 64.5% in the 3rd quarter. Franklin Resources Inc. now owns 18,983 shares of the company’s stock worth $937,000 after buying an additional 7,442 shares during the last quarter. Virtu Financial LLC increased its stake in Janux Therapeutics by 48.0% in the third quarter. Virtu Financial LLC now owns 7,463 shares of the company’s stock valued at $339,000 after acquiring an additional 2,419 shares during the last quarter. Neo Ivy Capital Management bought a new position in Janux Therapeutics in the third quarter valued at $940,000. Geode Capital Management LLC raised its position in Janux Therapeutics by 6.2% during the third quarter. Geode Capital Management LLC now owns 662,594 shares of the company’s stock valued at $30,107,000 after purchasing an additional 38,490 shares in the last quarter. Finally, Barclays PLC lifted its stake in Janux Therapeutics by 496.5% during the third quarter. Barclays PLC now owns 174,061 shares of the company’s stock worth $7,907,000 after purchasing an additional 144,883 shares during the last quarter. 75.39% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Leerink Partnrs raised Janux Therapeutics to a “strong-buy” rating in a report on Friday, November 22nd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $100.00 target price on shares of Janux Therapeutics in a research note on Thursday, November 7th. Stifel Nicolaus began coverage on shares of Janux Therapeutics in a research report on Friday, September 6th. They issued a “buy” rating and a $70.00 price target on the stock. Scotiabank cut their price objective on shares of Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating for the company in a report on Friday, August 9th. Finally, UBS Group started coverage on shares of Janux Therapeutics in a report on Thursday, October 24th. They set a “buy” rating and a $69.00 target price on the stock. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $67.70.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.